[Diabetologia] Researchers examined whether physiological changes in blood glucose levels in vivo control islet metallothionein 1 gene expression similarly to ex vivo observations, and identify the mechanisms involved.

[Bioscience Reports] The activation of GPR56 by its endogenous ligand Coll III improves pancreatic β-cell function. Scientists, through the alignment of collagen type III (Coll III) and G protein-coupled receptor 56 (GPR56) genomic DNA, revealed three complementary nucleotide regions, enabling the design of three short peptides.

[Molecular and Cellular Biochemistry] Investigators aimed to determine whether octreotide attenuates dibutyltin dichloride-induced pancreatic fibrosis through suppression of high-mobility group box 1 (HMGB1) and downstream Wnt/β-catenin signaling.

[Nature Genetics] To understand how heterogeneity contributes to PDAC biology, researchers analyzed a large cohort of primary tumors profiled using single-cell RNA sequencing to map clonal, transcriptional and spatial diversity.

[ACS Applied Materials & Interfaces] Scientists reported a sequential dual-nanoparticle approach that integrates extracellular matrix remodeling with tumor-targeted chemotherapy to overcome barriers in liposomal doxorubicin formulations for pancreatic cancer.

[Journal of Enzyme Inhibition and Medicinal Chemistry] Researchers used the scaffold of F389-0746, a selective benzoxazine-based MAP4K4 inhibitor with anti-cancer activity in pancreatic cancer, to guide the selection and evaluation of benzoxazine-based analogs, followed by biochemical, structural, selectivity, and cellular characterization of the most potent analogue.

[Current Oncology Reports] Investigators provide a critical narrative synthesis of Actinomycetota-derived metabolites evaluated in pancreatic cancer models, with every potency value re-derived from the primary literature and interpreted alongside assay conditions and available mechanistic and in vivo evidence.

[Expert Review of Gastroenterology & Hepatology] The authors critically review epidemiological, mechanistic, and causal evidence linking chronic pancreatitis (CP) with PDAC, focusing on heterogeneity across CP subtypes and disease trajectories.

[Cancer] The authors synthesize RAS biology, molecular-testing implications, clinical efficacy and toxicity data, and ongoing phase II and phase III trials for PDAC.

[Medicovestor, Inc. (Globe Newswire)] Medicovestor, Inc. announced that the US FDA has granted Fast Track designation to MC001, its lead investigational first-in-class chemoimmunotherapy antibody-drug-conjugate (ADC) for pancreatic cancer.

[The University of Toledo] Dr. Kuo-Hui Su, assistant professor in the Department of Cell and Cancer Biology at the University of Toledo, has been awarded a two-year, $80,000 grant from Ohio Cancer Research to investigate a potential new approach to treating pancreatic cancer — one that targets the disease’s ability to resist the treatments designed to fight it.

[Marker Therapeutics, Inc.] Marker Therapeutics, Inc. announced that the Company has been awarded $2.6 million from the US FDA which will support a Phase I clinical study evaluating the Company’s lead investigational multi-antigen recognizing (MAR)-T cell therapy, MT-601, in patients with locally advanced unresectable pancreatic cancer.